Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Entera Health, Inc
ClinicalTrials.gov Identifier:
NCT01828593
First received: April 8, 2013
Last updated: March 10, 2014
Last verified: March 2014

April 8, 2013
March 10, 2014
April 2013
January 2014   (final data collection date for primary outcome measure)
Frequency of daily unformed bowel movements [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Frequency of daily bowel movements [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01828593 on ClinicalTrials.gov Archive Site
  • Plasma concentration of Vitamin D and E [ Time Frame: through 6 months ] [ Designated as safety issue: No ]
  • Nutrient absorption [ Time Frame: through 6 months ] [ Designated as safety issue: No ]
  • Body measurements: weight, mid-upper arm circumference (MUAC), waist:hip ratio, body mass index (BMI), total body water (TBW), fat-free mass (FFM), body cell mass (BCM) [ Time Frame: through 6 months ] [ Designated as safety issue: No ]
  • Daily stool consistency [ Time Frame: through 6 months ] [ Designated as safety issue: No ]
  • Gastrointestinal symptoms [ Time Frame: through 6 months ] [ Designated as safety issue: No ]
Same as current
Effects of SBI on pro-inflammatory intestinal microbial populations, bacterial translocation, intestinal barrier function, and systemic immune activation [ Time Frame: through 6 months ] [ Designated as safety issue: No ]
Same as current
 
Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy
Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Study Evaluating the Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in HIV+ Subjects With HIV-associated Enteropathy.

The purpose of the study is to evaluate the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g BID and SBI 5.0 g versus placebo on supporting nutrient absorption in HIV+ subjects with HIV-associated enteropathy.

This study is evaluating the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5g BID and SBI 5.0g compared to placebo for 6 months on gastrointestinal symptoms, nutritional status and quality of life in HIV+ subjects with HIV-associated enteropathy. In addition, the effects of SBI on pro-inflammatory intestinal microbial populations, bacterial translocation, intestinal barrier function, and systemic immune activation will be investigated.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
HIV-associated Enteropathy
Other: Serum-derived bovine immunoglobulin protein isolate (SBI)
SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
  • Placebo Comparator: Placebo
  • Active Comparator: SBI 2.5 g
    Serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g
    Intervention: Other: Serum-derived bovine immunoglobulin protein isolate (SBI)
  • Active Comparator: SBI 5.0g
    Serum-derived bovine immunoglobulin protein isolate (SBI)5.0g
    Intervention: Other: Serum-derived bovine immunoglobulin protein isolate (SBI)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
90
September 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • History of HIV-1 infection
  • Plasma HIV viral load ≤40 copies/mL
  • Maintained virologic suppression for 1 year
  • Stable ART regimen
  • History of HIV-associated diarrhea defined as abnormal passage of 3 or more unformed stools per day or a liquid stool volume greater than 200 g per day for at least 4 weeks duration

Exclusion Criteria:

  • Positive stool test for pathogenic bacteria, C. difficile or ova and parasites
  • Conditions that require chronic therapy that is known to alter gut microbiota
  • Antibiotics within 2 weeks of screening (exception: prophylaxis antibiotics)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01828593
EH6001
No
Entera Health, Inc
Entera Health, Inc
Not Provided
Principal Investigator: David M Asmuth, M.D. University of California, Davis
Entera Health, Inc
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP